Tag Archives: finance

Experience the Innovation at RESI Boston 2025! 

3 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Innovator’s Pitch Challenge (IPC) is a highlight of RESI Boston, bringing early-stage life science startups into the spotlight. Finalists will present across multiple sessions, showcasing breakthroughs in therapeutics, medical devices, diagnostics, digital health solutions, and R&D tools. Each pitch is delivered to a panel of active investors and industry experts who provide interactive questions and constructive feedback, while attendees also get a front-row seat to see the next wave of healthcare innovation.

RESI attendees are more than just spectators; they play an active role in the competition by “investing” their RESI cash in the companies they believe in most. This unique format allows the community to engage directly with the innovators, and the winners are revealed after the votes are tallied during the closing cocktail reception.

IPC participants also benefit from one-on-one partnering, exhibit space in the RESI Exhibition Hall, and the chance to compete for complimentary registration at future RESI conferences. Here are the presenting companies at RESI Boston September:

While applications to the IPC are now closed, you can still register for RESI Boston September 2025 to take part in everything the conference has to offer — from casting your vote in the IPC, to connecting with investors, attending panels and workshops, and making valuable new partnerships.

Tags: , , , , , ,

Corporate VC Panel: Venture and Innovation Arms Making Strategic Investments

3 Sep

By Joey Wong, Director of Investor Research, Hong Kong BD, LSN

Joey-New-Headshot

Many large corporations establish ventures or innovation arms to invest in and partner with life science and healthcare startups. Unlike traditional institutional VCs, corporate venture capital (CVC) groups bring unique strategies, goals, and ties to their parent organizations. Some CVCs focus closely on opportunities that align with the corporation’s core businesses, while others pursue innovation beyond existing portfolios, creating broader avenues for collaboration.

This 50-minute discussion will bring together leaders from corporate venture arms of global pharma, biotech, medtech, and healthcare corporations. Panelists will share how they evaluate early-stage opportunities, what distinguishes their investment criteria from institutional VCs, and how they balance strategic alignment with financial return. Startups will also gain valuable perspective on how to approach CVCs, what additional benefits they can expect beyond funding, and how relationships and collaboration may evolve post-investment.

For entrepreneurs seeking strategic partners, this session offers a chance to hear directly from active CVC investors about how they drive innovation, accelerate R&D, and bring transformative solutions to the market.

Andrew-Merken
Andrew Merken
Shareholder
Polsinelli PC
(Moderator) 		Komeil-Nasrollahi
Komeil Nasrollahi
Sr. Director Innovation & Venture Partnerships
Siemens Healthineers 		Claire-Leurent
Claire Leurent
Managing Director
AbbVie Ventures
Jeffrey-Moore
Jeffrey Moore
President
MP Healthcare Venture Management (MPH) 		Alex-de-Winter
Alex de Winter
VP of New Ventures
Danaher Corporation

Join us at RESI Boston this September to take part in this discussion and connect with investors across the life science and healthcare ecosystem.

Tags: , , , , ,

Hot Investor Mandate: Corporate Venture Arm of Global Manufacturing Company Makes Strategic Investments in Medical Devices, Diagnostics, and Biomanufacturing

26 Aug

A global manufacturing company operates across a wide range of industries, including analytical, medical, and industrial equipment. In recent years, the firm has placed a strong focus on healthcare, particularly in clinical diagnostics and biomanufacturing. 

A few years ago, the firm established a corporate venture capital (CVC) division to seek strategic partnerships with companies that possess cutting-edge technologies aligned with its business areas.  

The firm has invested in companies across the U.S., Canada, and Asia and is actively looking to expand its portfolio. While the CVC primarily targets investments in Seed to Series A rounds, it may also consider Series B opportunities. Typical check sizes range from $1 million to $5 million USD, though larger investments are possible for particularly promising technologies. 

Within healthcare, the firm is seeking opportunities in clinical diagnostics, medical devices, and biomanufacturing. The firm is open to not only hardware but also consumables and software solutions. 

To attract investment from the CVC, having a lead investor is desirable. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: USA-Based VC Firm Seeks Novel Therapeutics and Platform Technologies, Investing Up to $30M Over Company Lifecycle

26 Aug

A venture capital firm based in the US is actively investing in life science companies. The firm primarily invests in therapeutics companies in early and growth stage. Typical check sizes are in the $25-30M range over the company’s life cycle. The firm has a preference for companies based in Los Angeles and is passionate about fostering the local life science ecosystem, but the firm is also open to investing outside of LA given that the opportunity is a great fit. Outside of LA, the firm invests almost exclusively in the US. 
 
The firm invests in therapeutics in all disease areas and modalities, and is open to both single assets and platform technologies. The firm currently has over 20 companies in their portfolio, which can be reviewed here: https://westlakebio.com/portfolio for a better sense of where the firm has invested to date.  

The firm is open to pre-clinical to early clinical stage opportunities. The firm is open to investing in promising companies even in the idea/conception stage, and has done so in the past. 
 
The firm looks for compelling technologies and is open to investing in companies founded by first-time entrepreneurs. The firm prefers to be a lead investor, and has always led Series A investments and seeks board representation when leading. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Venture and Growth Investment Firm Seeks Early-Stage Life Sciences Companies in the US, Open to All Sectors

26 Aug

A growth and venture investor based in the U.S. typically engages in pre-clinical and Seed stage life science startups. The firm invests in companies focused on significant unmet medical needs across contract services, manufacturing, equipment, and therapeutic companies. The firm supports entrepreneurs and early-stage companies by providing deep expertise, industry knowledge, and a network of proven experts to guide them through every stage of their life cycle. 

The firm is interested in pre-clinical therapeutics, digital health, medical devices, and diagnostic companies. The firm also invests in contract services, enabling technologies, and therapeutics across cell and gene therapies, oncology, antimicrobial resistance, neurosciences, and rare diseases. While indication-agnostic, the firm has particular expertise in oncology, neurosciences, rare disease, and antimicrobial resistance. 

The firm does not have strict company or management team requirements. The firm may take a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Early-Stage VC Firm Invests in Medtech Companies in Seed to Series A Rounds, Seeking Companies Across the Globe

26 Aug

A global, early-stage medtech venture capital firm with offices in North America and Asia has a particular focus on investing in underfunded regions globally. The firm invests in Seed and Series A rounds, with a typical check size of $250K – $1M in the form of equity. The firm will typically co-invest, and invests in 6-8 companies per year. The firm will invest globally. 
 
The firm invests in early-stage medtech companies developing life science technologies for large, unmet market needs. The firm focuses on medical devices and digital health. 
 
The firm prefers to work with experienced founders. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Investor Panels at RESI Boston September

26 Aug

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Life Science Nation (LSN) team is preparing to welcome the global life science ecosystem to Boston for the upcoming RESI conference this September. With an engaging lineup of investor panels, workshops, and the Innovator’s Pitch Challenge, founders and CEOs will have the opportunity to connect directly with investors while gaining tactical insights into fundraising and partnership strategies.

The RESI Boston program features seven investor panels spanning impact investing, mental health, oncology, diagnostics, family offices, corporate venture capital, and big pharma partnerships. These panels bring together a diverse group of experts—from venture funds and strategic investors to philanthropic groups and family offices—each offering unique perspectives on how they evaluate life science and healthcare opportunities.

Each 50-minute session will provide a candid look at what drives investor interest in early-stage ventures, what makes a company stand out in competitive landscapes, and how founders can build lasting relationships with the capital sources they need.

RESI Boston is not just about learning—it’s about engagement. Panelists will share their perspectives on industry landscapes, while also fielding questions and offering insights that directly address the challenges entrepreneurs face. These conversations are intended to bridge the gap between companies and capital providers, fostering the connections that fuel healthcare innovation.

Below is the schedule of investor panels at RESI Boston this September:

John-Abeles
John Abeles
General Partner
Northlea Partners 		Marc-Appel
Marc Appel
Managing Partner
Pacific Bridge NY 		Jonathan-Behr
Jonathan Behr
Partner
Dementia Discovery Fund
David Berry
David Berry
Managing Partner
Averin Capital 		Hyelim-Cho
Hyelim Cho
Sr. Director, BD and Alliance Management
RayzeBio
(a Bristol Myers Squibb company) 		Alex-de-Winter
Alex de Winter
Vice President of New Ventures
Danaher Corporation
Yizhen-Dong
Yizhen Dong
Managing Partner
Raise Health 		David-Fogel
David Fogel
Member of Screening & Due Diligence Committees
Mass Medical Angels 		Eric-Furfine
Eric Furfine
CEO & CSO
Mosaic Biosciences
Navin-Govind
Navin Govind
Partner
Evidence Ventures 		Andres-Hurtado-Lorenzo
Andres Hurtado-Lorenzo
SVP, Translational Research & IBD Ventures
Crohn's and Colitis Foundation 		Anula Jayasuriya
Anula Jayasuriya
Co-Founder and Partner
Kidron Capital
Arianne Kidder
Arianne Kidder
Partner
Seae Ventures 		Claire-Leurent
Claire Leurent
Managing Director
AbbVie Ventures 		Ron-Levin
Ron Levin
Managing Partner
Alumni Ventures
Vivian-Li
Vivian Li
Investor
K2 Venture Partners 		Michael Loftus
Michael Loftus
Director
PoC Capital 		Nune-Martiros
Nune Martiros
Senior Associate
Paladin Capital Group
Jeffrey-Moore
Jeffrey Moore
President
MP Healthcare Venture Management (MPH) 		Chris Murray
Chris Murray
Principal
MVM Life Science Partners 		Nikhil Mutyal
Nikhil Mutyal
Head of Search and Evaluation, Respiratory and Immunology
AstraZeneca
Komeil-Nasrollahi
Komeil Nasrollahi
Sr. Director Innovation & Venture Partnerships
Siemens Healthineers 		Stephanie Oestreich
Stephanie Oestreich
Managing Director
Myeloma Investment Fund 		Armin-Rump
Armin Rump
Director of Global BD
Otsuka Pharmaceutical Co., Ltd.
Jeremy-Sohn
Jeremy Sohn
Managing Partner
P74 Ventures 		Mike-Thomas
Mike Thomas
Managing Partner
Bold Brain Capital 		John-Tremblay
John Tremblay
Investor
Launchpad Venture Group
Chensu-Wang
Chensu Wang
Investment Manager
Yonjin Venture 		Jenny-Wang
Jenny Wang
Director, Search & Evaluation, Oncology
AbbVie 		Tyler-Wanke
Tyler Wanke
Investor
Wanke Family Office

Whether you are developing novel therapeutics, diagnostics, medical devices, or digital health solutions, the investor panels at RESI Boston will deliver the knowledge and networking opportunities to help you advance your fundraising journey.

Tags: , , , , ,

← Older Entries
Newer Entries →